TIDMIMM
RNS Number : 7193U
Immupharma PLC
30 June 2009
?
+------------------------------------+------------------------------------+
| For Immediate Release | 30 June 2009 |
+------------------------------------+------------------------------------+
ImmuPharma PLC
Annual Report and Accounts
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the
specialist drug discovery and development company, confirms that the Annual
Report and Accounts for the year ended 31 December 2008, has been posted to
shareholders.
The annual report is available, in electronic form, for download on the
Company's website www.immupharma.com.
The Company's Annual General Meeting will be held on 24 July 2009 at 11am at 50
Broadway, London, SW1H 0BL.
Ends
For further information please contact:
+------------------------------------+------------------------------------+
| ImmuPharma PLC: | |
+------------------------------------+------------------------------------+
| Dimitri Dimitriou, Chief Executive | +44 20 7152 4080 |
| Officer | |
+------------------------------------+------------------------------------+
| Richard Warr, Chairman | +44 20 7152 4080 |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Buchanan Communications | + 44 20 7466 5000 |
+------------------------------------+------------------------------------+
| Lisa Baderoon | |
+------------------------------------+------------------------------------+
| Rebecca Skye Dietrich | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Panmure Gordon & Co | |
+------------------------------------+------------------------------------+
| Andrew Burnett | +44 151 243 0963 |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSFLMFTMMMTBPL
|